**Supplementary Table. Geometric means and proportion of detectable measurements**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   |   |   |   | **NVAS** | **Placebo** |
|   |   |   | in range | n=143 | n=65 |
|   |   |   | GM (95% CI) | GM (95% CI) |
| TNF-α | d3 | medium | 75% | 51 (36-73) | 55 (33-93) |
|   |   | PHA | 99% | 402 (332-487) | 367 (276-488) |
|   |   | PPD | 98% | 286 (228-358) | 270 (194-376) |
|   |   | TT | 96% | 352 (260-478) | 290 (184-456) |
|   |   | Pam | 87% | 55 (45-68) | 53 (39-73) |
|   | d1 | medium | 85% | 67 (51-87) | 75 (50-111) |
|   |   | LPS | 100% | 663 (577-762) | 653 (532-803) |
| IL-13 | d3 | medium\* | 20% | 20 (14-28) | 22 (14-34) |
|   |   | PHA | 91% | 113 (88-145) | 96 (66-139) |
|   |   | PPD | 56% | 13 (10-16) | 13 (9-18) |
|   |   | TT | 73% | 33 (25-43) | 28 (18-42) |
| IL-17 | d3 | medium\* | 23% | 24 (18-32) | 20 (12-33) |
|   |   | PHA | 89% | 50 (42-61) | 37 (28-49) |
|   |   | PPD\* | 49% | 53 (45-62) | 42 (31-55) |
|   |   | TT | 64% | 20 (15-26) | 17 (12-25) |
| IL-10 | d3 | medium\* | 35% | 32 (26-41) | 42 (31-55) |
|   |   | PHA | 95% | 32 (26-38) | 24 (19-32) |
|   |   | PPD | 80% | 20 (16-26) | 13 (9-19) |
|   |   | TT | 61% | 9 (7-13) | 9 (5-14) |
|   |   | Pam | 98% | 56 (47-67) | 47 (36-60) |
|   | d1 | medium | 64% | 12 (8-19) | 16 (9-29) |
|   |   | LPS | 100% | 451 (388-524) | 387 (310-483) |
| IFN-γ | d3 | medium\* | 11% | 10 (6-16) | 14 (8-25) |
|   |   | PHA | 90% | 59 (42-82) | 78 (47-129) |
|   |   | PPD | 87% | 55 (40-75) | 66 (41-104) |
|   |   | TT | 74% | 26 (18-39) | 20 (11-35) |
| IL-5 | d3 | medium\* | 10% | 9 (5-15) | 11 (5-22) |
|   |   | PHA | 87% | 54 (38-76) | 47 (28-78) |
|   |   | PPD | 72% | 11 (8-15) | 9 (6-15) |
|   |   | TT | 80% | 35 (24-51) | 27 (15-47) |
|   |   |   | in range | n=167 | n=73 |
|   |   |   | GM (95% CI) | GM (95% CI) |
| plasma |   | IL-1Ra | 100% | 2,331 (2,192-2,479) | 2,161 (1,969-2,371) |
|   |   | MCP-1 | 100% | 141 (135-148) | 150 (139-160) |
|   |   | TNF-α | 99% | 12 (11-13) | 13 (12-14) |
|   |   | IL-10\* | 42% | 42 (35-51) | 41 (31-55) |
|   |   | IL-8 | 100% | 21 (19-22) | 21 (19-23) |
|   |   | IL-6\* | 11% | 10 (6-16) | 13 (7-25) |
|   |   | suPAR | 100% | 4.5 (4.4-4.7) | 4.5 (4.3-4.7) |

Geometric means (GM, with 95% confidence intervals) of the outcomes measured (pg/ml, except for suPAR which is in ng/ml). Geometric means are estimated by use of Tobit regression, where observations outside the assay range are included as missing in the model producing the GM estimates.

For outcomes with >50% of measurements below the lower detection limit, the proportion of measurements above the limit are presented, obtained by Poisson regression on the risk of a detectable measurement.

in range: Proportion of measurements above the lower limit of detection (i.e. within assay working range).

d1, d3: Day 1 and day 3 cultures, respectively.